- Home
- KWE vs MBRX Comparison
KWE vs MBRX Comparison
Compare KWE & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KWE
- MBRX
- Stock Information
- Founded
- KWE 2017
- MBRX 2015
- Country
- KWE Canada
- MBRX United States
- Employees
- KWE N/A
- MBRX N/A
- Industry
- KWE
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- KWE
- MBRX Health Care
- Exchange
- KWE Nasdaq
- MBRX Nasdaq
- Market Cap
- KWE 2.3M
- MBRX 11.3M
- IPO Year
- KWE N/A
- MBRX 2016
- Fundamental
- Price
- KWE $5.57
- MBRX $1.01
- Analyst Decision
- KWE
- MBRX Strong Buy
- Analyst Count
- KWE 0
- MBRX 2
- Target Price
- KWE N/A
- MBRX $6.00
- AVG Volume (30 Days)
- KWE 543.9K
- MBRX 273.3K
- Earning Date
- KWE 05-19-2025
- MBRX 05-13-2025
- Dividend Yield
- KWE N/A
- MBRX N/A
- EPS Growth
- KWE N/A
- MBRX N/A
- EPS
- KWE N/A
- MBRX N/A
- Revenue
- KWE $1,572,738.00
- MBRX N/A
- Revenue This Year
- KWE N/A
- MBRX N/A
- Revenue Next Year
- KWE N/A
- MBRX N/A
- P/E Ratio
- KWE N/A
- MBRX N/A
- Revenue Growth
- KWE 116.30
- MBRX N/A
- 52 Week Low
- KWE $0.22
- MBRX $0.40
- 52 Week High
- KWE $243.60
- MBRX $5.29
- Technical
- Relative Strength Index (RSI)
- KWE 51.37
- MBRX 50.79
- Support Level
- KWE $4.56
- MBRX $1.00
- Resistance Level
- KWE $7.10
- MBRX $1.09
- Average True Range (ATR)
- KWE 1.09
- MBRX 0.07
- MACD
- KWE 0.28
- MBRX 0.01
- Stochastic Oscillator
- KWE 76.66
- MBRX 60.78
About KWE KWESST Micro Systems Inc.
KWESST Micro Systems Inc develops and commercializes next-generation tactical systems. The company offers breakthrough technology in lethal and non-lethal systems with broad application, including law enforcement and personal defence, modernized digitization of tactical forces for shared situational awareness and targeting, and counter-measures against threats such as drones, lasers and electronic detection.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.